Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
ApicHope Pharmaceutical Co., Ltd Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
14 August 2026
A 2026 BD opportunity scan of ApicHope Pharmaceutical Co., Ltd, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.
Latest Hotspot
8 min read
Daewon Pharmaceutical Co, Ltd Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
14 August 2026
A 2026 BD opportunity scan of Daewon Pharmaceutical Co, Ltd, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.
Latest Hotspot
8 min read
Taisho Pharmaceutical Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
14 August 2026
A 2026 BD opportunity scan of Taisho Pharmaceutical Co., Ltd., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.
Latest Hotspot
8 min read
Aureka Biotechnologies Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
14 August 2026
A 2026 BD opportunity scan of Aureka Biotechnologies, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.
Latest Hotspot
12 min read
Hypoaldosteronism Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Hypoaldosteronism with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Acidosis, Renal Tubular Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Acidosis, Renal Tubular in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Gordon Syndrome Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Gordon Syndrome with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
SeSAME Syndrome Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate SeSAME Syndrome with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Hypomagnesemia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Hypomagnesemia with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Hypomagnesemia 5, Renal, With Ocular Involvement Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Hypomagnesemia 5, Renal, With in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Paralysis, Hyperkalemic Periodic Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Paralysis, Hyperkalemic in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Hypokalemic Periodic Paralysis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Hypokalemic Periodic Paralysis in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.